Glaucoma
An eye condition that damages the optic nerve, often linked to high pressure inside the eye, leading to slow, unnoticeable loss of peripheral vision.
Emergency Management: POAG is chronic. However, Acute Angle-Closure Glaucoma is an emergency requiring immediate IOP lowering with IV Acetazolamide, topical Pilocarpine, Timolol, and urgent Laser Peripheral Iridotomy (LPI).
Glaucoma is a group of progressive optic neuropathies characterized by degeneration of retinal ganglion cells and specific structural changes to the optic nerve head (cupping). Primary Open-Angle Glaucoma (POAG) is the most common form, typically associated with an elevated intraocular pressure (IOP), although IOP can be normal (Normal Tension Glaucoma).
Detailed Overview
POAG is a chronic, insidious disease. The eye's drainage system (trabecular meshwork) gradually becomes less efficient, causing aqueous humor to build up and increase intraocular pressure. This mechanical stress, combined with vascular insufficiency, damages the delicate nerve fibers at the optic disc. Because it initially affects the mid-peripheral visual field, the brain easily compensates, and patients are entirely asymptomatic until late in the disease. It is a leading cause of irreversible blindness globally.
Epidemiology & Demographics
Affects over 60 million people worldwide. Prevalence increases significantly with age. African Americans and Hispanics have a 3-4 times higher risk of developing POAG and suffer from more aggressive disease compared to Caucasians.
Etiological Mechanism
The exact cause of ganglion cell death is multifactorial, primarily involving mechanical compression due to elevated IOP and decreased optic nerve perfusion. In POAG, the anterior chamber angle is open, but there is microscopic resistance to aqueous outflow in the trabecular meshwork.
Primary Causes
Increased resistance in the Trabecular Meshwork
Genetic Predisposition (e.g., MYOC mutations)
Vascular dysregulation
Aqueous humor is produced by the ciliary body, flows through the pupil, and drains via the trabecular meshwork into Schlemm's canal. In POAG, glycosaminoglycan accumulation and endothelial dysfunction in the trabecular meshwork increase resistance to outflow. The resulting rise in IOP applies mechanical pressure to the lamina cribrosa at the optic nerve head. This impedes axonal transport in retinal ganglion cells and compromises microvascular perfusion. Apoptosis of ganglion cells ensues, leading to enlargement of the optic cup (cupping) and corresponding visual field deficits.
Diagnostic Criteria & Guidelines
Diagnosis requires demonstrating characteristic optic nerve damage (via dilated fundus exam and OCT showing retinal nerve fiber layer thinning) AND corresponding visual field defects (via automated perimetry). Gonioscopy is required to confirm the angle is open.
Topical Prostaglandin Analogs (e.g., Latanoprost 0.005% one drop daily at bedtime). Increases uveoscleral outflow. Highly effective, lowering IOP by 25-30%. Selective Laser Trabeculoplasty (SLT) is now also considered a first-line alternative to drops for POAG.
Second-Line & Adjunctive Therapy
Topical Beta-Blockers (e.g., Timolol 0.5% BID) - decreases aqueous production; contraindicated in asthma/COPD. Alpha-2 Agonists (Brimonidine 0.2% TID). Carbonic Anhydrase Inhibitors (Dorzolamide 2% TID). Often used in combination if target IOP is not met.
Surgical & Procedural Management
Minimally Invasive Glaucoma Surgery (MIGS) such as iStent, often done concurrently with cataract surgery. For advanced/refractory cases: Trabeculectomy (creating a fistula for fluid to drain under the conjunctiva) or Glaucoma Drainage Devices (Tube shunts).
Patient Counseling & Advice
Emphasize that treatments cannot restore lost vision, only preserve what is left. Therefore, they must use their eye drops every day for the rest of their lives, even though their eyes 'feel fine'. Warn about Latanoprost side effects (iris color darkening, eyelash growth).
Follow-Up & Monitoring Schedule
Patients require life-long monitoring. IOP checks every 3-6 months. Visual fields and OCT imaging performed every 6-12 months to monitor for disease progression. If progression is noted, the 'Target IOP' must be lowered further.
Preventive Strategies
Comprehensive dilated eye exams every 1-2 years for individuals over 40 (especially African Americans and those with family history) to catch the disease in the asymptomatic stage.
With early diagnosis and strict adherence to treatment, the vast majority of patients retain useful vision for their lifetime. Untreated, it invariably progresses to total blindness.